| 104804-0 |
Medication substitution criterion |
Find |
Medication |
Pt |
Nar |
|
|
ACTIVE |
Medication substitution criterion Medication Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MEDS |
|
104804-0 |
|
|
|
|
Observation |
|
|
|
0 |
Med substitution criterion Medication |
|
|
|
N |
|
Finding; Findings; Med; Med substitution criterion; MEDS; Narrative; Point in time; Random; Report |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104805-7 |
Creatinine renal clearance.predicted |
VRat |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatinine renal clearance predicted |
|
ADD |
DefinitionDescription |
|
|
mL/min |
|
|
|
|
|
|
CHEM |
|
104805-7 |
|
|
|
|
Observation |
|
|
|
0 |
Creat Cl predicted SerPl-vRate |
|
|
|
N |
|
Chemistry; Cl; Cl predicted; Clear; Clearanc; Clearances; Clr; CR; Crea; Creat; Flow; Kidney; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Volume rate; vRate |
2.78 |
2.78 |
|
|
|
|
|
|
|
mL/min |
|
|
|
0 |
| 104806-5 |
Trichomonas vaginalis DNA |
PrThr |
XXX |
Pt |
Ord |
Molgen |
|
ACTIVE |
Trichomonas vaginalis DNA [Presence] in Specimen by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
104806-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
T vaginalis DNA Spec Ql |
|
|
|
N |
|
Deoxyribonucleic acid; Microbiology; Misc; Miscellaneous; Molecular genetics; Ordinal; Other; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; T vaginalis; To be specified in another part of the message; Tric; Trich; Trichimoniasis; Trichomonad; Trichomonads; Trichomoniasis; Unspecified |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104807-3 |
Medication cessation date time |
Date |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Medication cessation date time |
|
ADD |
DefinitionDescription |
|
|
MMDDYY |
|
|
|
|
|
|
MEDS |
|
104807-3 |
|
|
|
|
Observation |
|
|
|
0 |
Med cessation date time |
|
|
|
N |
|
End; Med cessation date time; MEDS; Pause; Point in time; QNT; Quan; Quant; Quantitative; Random; Suspend; Termination |
2.78 |
2.78 |
|
|
|
|
|
|
|
{mm/dd/yyyy} |
|
|
|
0 |
| 104808-1 |
Medication dispense priority |
Find |
Medication |
Pt |
Nar |
|
|
ACTIVE |
Medication dispense priority Medication Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MEDS |
|
104808-1 |
|
|
|
|
Observation |
|
|
|
0 |
Med dispense priority Medication |
|
|
|
N |
|
Finding; Findings; Med; Med dispense priority; MEDS; Narrative; Point in time; Random; Report |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104809-9 |
Medication dosage justification |
Find |
Medication |
Pt |
Nar |
|
|
ACTIVE |
Medication dosage justification Medication Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MEDS |
|
104809-9 |
|
|
|
|
Observation |
|
|
|
0 |
Med dosage justification Medication |
|
|
|
N |
|
Finding; Findings; Med; Med dosage justification; MEDS; Narrative; Point in time; Random; Report |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 10481-0 |
Follitropin.alpha subunit Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Follitropin.alpha subunit Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
10481-0 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
A-FSH Ag Tiss Ql ImStn |
|
|
|
|
|
A-FSH; Alfa; Antigen; Antigens; Follicle stimulating hormone; FSH; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Pituitary glycoproteins; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 104810-7 |
Medication total daily amount |
Num |
Medication |
24H |
Qn |
|
|
ACTIVE |
Medication total daily amount [#] 24 hour Medication |
|
ADD |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
MEDS |
|
104810-7 |
|
|
|
|
Observation |
|
|
|
0 |
Med total daily amt 24h Medication |
|
|
|
N |
|
1 day; 24 hours; 24HR; Cnt; Count; Med; Med total daily amt; MEDS; Number; QNT; Quan; Quant; Quantitative; Tot; Totl |
2.78 |
2.78 |
|
|
|
|
|
|
|
{#} |
|
|
|
0 |
| 104811-5 |
Epstein Barr virus DNA |
LnCnc |
XXX |
Pt |
Qn |
Molgen |
|
ACTIVE |
Epstein Barr virus DNA [Log #/volume] in Specimen by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
log copies/mL |
|
|
|
|
|
|
MICRO |
|
104811-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
EBV DNA Spec-Log# |
|
|
|
N |
|
Deoxyribonucleic acid; EBV; Epstn; HHV-4; human herpesvirus 4; Log NCNC; Log#; Microbiology; Misc; Miscellaneous; Molecular genetics; Mono; Mononucleosis; Other; PCR; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; To be specified in another part of the message; Unspecified |
2.78 |
2.78 |
|
|
|
|
|
|
|
{Log_copies}/mL |
|
|
|
0 |
| 104812-3 |
Base excess |
SCnc |
BldCoV |
Pt |
Qn |
|
|
ACTIVE |
Base excess in Venous cord blood |
|
ADD |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
104812-3 |
|
|
|
|
Observation |
|
|
|
0 |
Base excess BldCoV-sCnc |
|
|
|
N |
|
Base ex; BE; Bld cord; BSE; Chemistry; Cord BldV; Cord venous blood; EXS; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration |
2.78 |
2.78 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 104813-1 |
Gamma globulin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Gamma globulin [Mass/volume] in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
mg/L |
|
|
|
|
|
|
CHEM |
|
104813-1 |
|
|
|
|
Observation |
|
|
|
0 |
Gamma glob SerPl-mCnc |
|
|
|
N |
|
Chemistry; GLB; Glob; Glob%; Globul; Globulins; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; Protein gamma globulin; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.78 |
2.78 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 104814-9 |
Lactate dehydrogenase 1/Lactate dehydrogenase.total |
CFr |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Lactate dehydrogenase 1/Lactate dehydrogenase.total in Urine |
|
ADD |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
MICRO |
|
104814-9 |
|
|
|
|
Both |
|
|
|
0 |
LDH1 Ur-CFr |
|
|
|
N |
|
2-Hydroxypropanoic acid; 2-hydroxy-propionate; 2-hydroxy-propionic acid; Catalytic Fraction; Dehydrog; Dehyrdogenase; i; L.D.H; Lact; Lactate dehydrogenase.fraction 1; Lactic acid; Lactic acid dehydrogenase; LD; LD1; LD-1; LDH; LDH isoenzyme 1; LDH1; L-lactate; L-lactate dehydrogenase; Microbiology; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; Tot; Totl; Tumor marker; UA; UR; Urn |
2.78 |
2.78 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 104815-6 |
Chlamydia trachomatis DNA |
PrThr |
XXX |
Pt |
Ord |
Molgen |
|
ACTIVE |
Chlamydia trachomatis DNA [Presence] in Specimen by Molecular genetics method |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
104815-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
C trach DNA Spec Ql |
|
|
|
N |
|
C trac; C trach; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; Deoxyribonucleic acid; LGV; Lymphogranuloma venereum; Microbiology; Misc; Miscellaneous; Molecular genetics; Ordinal; Other; PCR; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Trachoma; Unspecified |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104816-4 |
Beta hydroxybutyrate |
SCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Beta hydroxybutyrate [Moles/volume] in Blood |
|
ADD |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
104816-4 |
|
|
|
|
Both |
|
|
|
0 |
B-OH-Butyr Bld-sCnc |
|
|
|
N |
|
3-hydroxybutyrate; 3-hydroxybutyric acid; B; Beta hydroxy butyrate; Beta hydroxybutyric acid; Betahydroxybutyrate; Betahydroxybutyric acid; BHB; Blood; BOHB; B-OH-Butyr; Chemistry; Hydroxybutyric acid; Level; Point in time; QNT; Quan; Quant; Quantitative; Random; Substance concentration; WB; Whole blood |
2.78 |
2.78 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
| 104817-2 |
Medication administration method |
Find |
Medication |
Pt |
Nom |
|
|
ACTIVE |
Medication administration method Medication |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MEDS |
|
104817-2 |
|
|
|
|
Observation |
|
|
|
0 |
Medication admin method Medication |
|
|
|
N |
|
Finding; Findings; Med; Medication admin method; MEDS; Meth; Method of; Nominal; Point in time; Random |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104818-0 |
Medication parsable directions |
Type |
Medication |
Pt |
Nar |
|
|
ACTIVE |
Medication parsable directions Medication Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MEDS |
|
104818-0 |
|
|
|
|
Observation |
|
|
|
0 |
Med parsable directions Medication |
|
|
|
N |
|
Med; Med parsable directions; MEDS; Narrative; Point in time; Random; Report; Typ |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104819-8 |
Active ingredient strength |
Dosage |
Medication |
Pt |
Qn |
|
|
ACTIVE |
Active ingredient strength [Dosage] Medication |
|
ADD |
DefinitionDescription |
|
|
ug/mg/ml |
|
|
10/ug/20mg/ml |
|
|
|
MEDS |
|
104819-8 |
|
|
|
|
Observation |
|
|
|
0 |
Active ingredient strength Medication |
|
|
|
N |
|
Med; MEDS; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.78 |
2.78 |
|
|
|
|
|
|
|
ug/mg/ml |
|
|
|
0 |
| 10482-8 |
Follitropin.beta subunit Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Follitropin.beta subunit Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
10482-8 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
B-FSH Ag Tiss Ql ImStn |
|
|
|
|
|
Antigen; Antigens; B; B-FSH; Follicle stimulating hormone; FSH; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; PATHOLOGY; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified |
2.56 |
1.0i |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 104820-6 |
Medication dispense start date |
Date |
Medication |
Pt |
Qn |
|
|
ACTIVE |
Medication dispense start date Medication |
|
ADD |
DefinitionDescription |
|
|
MMDDYY |
|
|
|
|
|
|
MEDS |
|
104820-6 |
|
|
|
|
Observation |
|
|
|
0 |
Med dispense start date Medication |
|
|
|
N |
|
Med; Med dispense start date; MEDS; Point in time; QNT; Quan; Quant; Quantitative; Random; Started |
2.78 |
2.78 |
|
|
|
|
|
|
|
{mm/dd/yyyy} |
|
|
|
0 |
| 104821-4 |
Medication substrate strength |
Dosage |
Medication |
Pt |
Qn |
|
|
ACTIVE |
Medication substrate strength [Dosage] Medication |
|
ADD |
DefinitionDescription |
|
|
ug/mg/ml |
|
|
10/ug/20mg/ml |
|
|
|
MEDS |
|
104821-4 |
|
|
|
|
Observation |
|
|
|
0 |
Med substrate strength Medication |
|
|
|
N |
|
Med; Med substrate strength; MEDS; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.78 |
2.78 |
|
|
|
|
|
|
|
ug/mg/ml |
|
|
|
0 |
| 104822-2 |
Medication maximum dose amount |
Num |
Medication |
Pt |
Qn |
|
|
ACTIVE |
Medication maximum dose amount [#] Medication |
|
ADD |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
MEDS |
|
104822-2 |
|
|
|
|
Observation |
|
|
|
0 |
Medication max dose amt Medication |
|
|
|
N |
|
Cnt; Count; Med; Med max dose; Medication max dose amt; MEDS; Number; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.78 |
2.78 |
|
|
|
|
|
|
|
{#} |
|
|
|
0 |
| 104823-0 |
Medication alternate amount |
Num |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
Medication alternate amount [#] |
|
ADD |
DefinitionDescription |
|
|
# |
|
|
|
|
|
|
MEDS |
|
104823-0 |
|
|
|
|
Observation |
|
|
|
0 |
Medication alt amt |
|
|
|
N |
|
Cnt; Count; Medication alt amt; MEDS; Number; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.78 |
2.78 |
|
|
|
|
|
|
|
{#} |
|
|
|
0 |
| 104824-8 |
Therapeutic direction sequence |
Find |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Therapeutic direction sequence |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CLIN |
|
104824-8 |
|
|
|
|
Observation |
|
|
|
0 |
Therapeutic direction seq |
|
|
|
N |
|
CLIN; Finding; Findings; Nominal; Point in time; Random; Ther |
2.78 |
2.78 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 104825-5 |
Medication strength presentation information |
- |
Medication |
Pt |
- |
|
|
ACTIVE |
Medication strength presentation information Medication |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MEDS |
|
104825-5 |
|
|
|
|
Order |
|
|
|
0 |
Med strength present info Medication |
|
|
|
N |
|
Med; Med strength; Med strength present info; MEDS; Pan; Panel; PANEL.MEDS; Panl; Pnl; Point in time; Random |
2.78 |
2.78 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 104826-3 |
Erythrocyte/Specimen Volume |
VFr.DF |
Bld |
Pt |
Qn |
Calculated |
|
ACTIVE |
Hematocrit [Pure volume fraction] of Blood by calculation |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
HEM/BC |
|
104826-3 |
|
Calculated |
|
|
Observation |
|
|
|
0 |
Hct VFr.DF Bld Calc |
|
|
|
N |
|
Blood; Calc; Calculation; Discocyte; Erc; Erythrocytes; HEMATOLOGY/CELL COUNTS; Point in time; QNT; Quan; Quant; Quantitative; Random; RBC; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; Spec; Vol; WB; Whole blood |
2.79 |
2.78 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT:Hematocrit as a component is not an adequate description for a ratio, therefore Hematocrit is kept as a synonym, and the actual component is expressed as it should be:Erythrocyte/Specimen Volume; |
0 |
